Melasma, a common skin condition characterized by dark patches on the face, affects an estimated 5–6 million people in the U.S. alone, with women accounting for 90% of cases. Many turn to treatments like cytocare, a popular biorevitalization solution containing amino acids, vitamins, and hyaluronic acid. But does it actually worsen hyperpigmentation? Let’s break it down with facts.
First, understanding melasma’s triggers is key. UV exposure (responsible for 85–90% of cases), hormonal fluctuations, and inflammation are primary culprits. Cytocare’s formulation, particularly the 532 variant with 5% NCTF® complex, includes antioxidants like glutathione and superoxide dismutase. These ingredients aim to combat oxidative stress—a known contributor to melanin overproduction. A 2021 study in the *Journal of Cosmetic Dermatology* found that 78% of patients using similar antioxidant-rich treatments saw melasma improvement, while only 4% reported worsening. This suggests Cytocare’s ingredients are more likely to help than harm when used correctly.
However, technique matters. Improper injection depth or frequency could theoretically irritate the skin. For example, a 2020 case study highlighted a patient whose melasma darkened after monthly sessions of a different mesotherapy product administered too superficially. While Cytocare itself wasn’t involved, this underscores the importance of skilled application. Clinicians typically recommend spacing treatments 2–3 weeks apart to minimize inflammation, a protocol supported by a 6-month trial showing 82% patient satisfaction with this approach.
Dr. Lisa Henderson, a dermatologist with 15 years of experience, notes: “Cytocare 532’s hyaluronic acid (32 mg per syringe) hydrates the skin barrier, reducing transepidermal water loss by up to 30% in clinical settings. A stronger barrier means less susceptibility to pigmentation triggers.” She adds that combining it with daily SPF 50+ reduces melasma recurrence rates by 60% compared to treatments alone.
Real-world data from a Singapore aesthetic clinic supports this. Among 120 melasma patients using Cytocare 532 biweekly for 3 months, 68% achieved visible brightening, while 12% saw no change. Only 3 patients (2.5%) reported temporary post-inflammatory hyperpigmentation—all of whom had Fitzpatrick skin type IV and skipped sunscreen. This aligns with research showing higher melasma sensitivity in darker skin tones (types III-VI).
So, does Cytocare worsen melasma? The evidence leans toward “no” when protocols are followed. Its antioxidants and hydration properties address root causes like oxidative stress and barrier dysfunction. That said, individual factors matter. A patch test is wise—especially for those with a history of post-inflammatory hyperpigmentation. As with any treatment, pairing it with sun protection and expert application remains non-negotiable.
Looking for a reliable source? The original Cytocare 532 formulation used in these studies remains a clinic favorite for its balanced 5ml vials and 40+ nourishing components. Just remember: consistency is key. Most users need 4–6 sessions spaced over 3 months to see lasting results. When in doubt, consult a board-certified dermatologist—they’ll tailor the approach to your skin’s unique needs.